Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,759.00-1.62%ETH$2,400.36-3.30%GOLD$4,385.60+1.22%OIL$104.06-1.67%
Smart Investors Daily
TR

NASDAQ · TRIB

Trinity Biotech plc

Healthcare · Medical - Diagnostics & Research

$7.33

Down-$0.15 (-1.94%)

Updated Sep 16, 2026, 1:06 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
11.32M
P/E ratio
-0.54
Dividend yield
0.00%
52-week range
$0.31 – $14.17
Volume
13.5K
Avg. volume
97.99K

Price performance

TRIB price history

1M range · 20 trading sessions · Daily adjusted prices

TRIB closed at $7.33 after 20 trading sessions, down 41.07% for the selected period.

Last close
$7.33
Period change
-41.07%
Period low
$7.33
Period high
$12.43
Daily close
View OHLC price history
TRIB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$7.77$7.77$7.17$7.32513.5K
Sep 14, 2026$7.30$7.63$7.30$7.477.05K
Sep 11, 2026$7.99$7.99$6.85$7.7412.1K
Sep 10, 2026$7.63$7.87$7.30$7.7919.68K
Sep 9, 2026$9.4708$9.52$8.00$8.0027.24K
Sep 8, 2026$9.31$9.671$8.8022$9.0610.06K
Sep 4, 2026$9.50$9.84$9.2402$9.4111.24K
Sep 3, 2026$9.62$9.90$9.235$9.6020.37K
Sep 2, 2026$9.60$9.85$9.45$9.6012.07K
Sep 1, 2026$9.76$9.95$9.325$9.7210.04K
Aug 31, 2026$9.61$10.205$9.51$9.8714.55K
Aug 28, 2026$9.83$9.83$9.2976$9.686.67K
Aug 27, 2026$9.86$10.32$9.75$9.7511.25K
Aug 26, 2026$9.71$10.035$9.49$9.5928K
Aug 25, 2026$10.98$10.98$9.6901$9.7166.78K
Aug 24, 2026$10.48$10.59$10.0001$10.336.86K
Aug 21, 2026$10.95$11.245$10.285$10.608.11K
Aug 20, 2026$11.19$12.10$10.25$10.5516.85K
Aug 19, 2026$12.12$12.25$10.3958$11.0155.48K
Aug 18, 2026$11.15$13.20$11.15$12.43127.06K

Latest TRIB news

The latest Smart Investors Daily articles mentioning TRIB.

Stock researchCompany · Overview

TRIB research

Overview

Company profile and research snapshot.

Company profile

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.06
Implied upside
—
Analysts
7
TRIB recent ratings
DateFirmRatingTarget
Oct 5, 2016Stephens & Co.Equal-weight—
Oct 5, 2016Stephens & Co.Equal-weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Trinity Biotech’s Trinovium Subsidiary Signs Contract to Supply Red Team Investments with Advanced Liquid Cooling Solutions for AI Data Center Infrastructure

Trinovium to supply RTI with advanced fluids and analytical systems for deployment in a U.S. commercial pilot focused on AI and high-performance computing data center infrastructure Data center power densities are increasing rapidly as AI workloads expand, creating greater thermal-management demands and interest in advanced liquid cooling solutions DUBLIN and WILSONVILLE, Ore., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company, today

Yahoo · Aug 28, 2026

Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

- Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - PrePsia™ patent portfolio expands to nine granted U.S. and European patents - Company issues update on Nasdaq listing DUBLIN, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, today provided an update on key developments across its diagnostics business, highlighting co

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By